<DOC>
	<DOCNO>NCT00299832</DOCNO>
	<brief_summary>Assessing safety , efficacy pharmacokinetics SPP100 ( Aliskiren ) regimen hypertensive patient renal dysfunction</brief_summary>
	<brief_title>SPP100 ( Aliskiren ) Regimen Hypertensive Patients With Renal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Age : 20 80 year old Gender : Male female Status : Outpatients Elevated Serum Creatinine Patients suspect malignant hypertension Patients clinically significant allergy Patients receive investigational drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension , aliskiren , blood pressure , rennin</keyword>
</DOC>